| scholarly article | Q13442814 |
| P356 | DOI | 10.1016/S0140-6736(09)60925-9 |
| P698 | PubMed publication ID | 19447241 |
| P2093 | author name string | Miguel Martin | |
| P2860 | cites work | Taxanes for adjuvant treatment of early breast cancer | Q24242987 |
| Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer | Q34496969 | ||
| Effect of the breast-cancer resistance protein on atypical multidrug resistance | Q34571843 | ||
| Single-step doxorubicin-selected cancer cells overexpress the ABCG2 drug transporter through epigenetic changes. | Q36662847 | ||
| Sequential docetaxel as adjuvant chemotherapy for early breast cancer (TACT): an open-label, phase III, randomised controlled trial | Q37206289 | ||
| Weekly paclitaxel in the adjuvant treatment of breast cancer. | Q37346811 | ||
| Long-term benefit of high-dose epirubicin in adjuvant chemotherapy for node-positive breast cancer: 15-year efficacy results of the Belgian multicentre study. | Q46185783 | ||
| Epirubicin increases long-term survival in adjuvant chemotherapy of patients with poor-prognosis, node-positive, early breast cancer: 10-year follow-up results of the French Adjuvant Study Group 05 randomized trial | Q46443839 | ||
| Adjuvant chemotherapy with sequential or concurrent anthracycline and docetaxel: Breast International Group 02-98 randomized trial. | Q46817262 | ||
| Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials | Q46828225 | ||
| Clinical relevance of transmembrane drug efflux as a mechanism of multidrug resistance. | Q54116698 | ||
| Benefit of taxanes as adjuvant chemotherapy for early breast cancer | Q61899631 | ||
| Sequential adjuvant epirubicin-based and docetaxel chemotherapy for node-positive breast cancer patients: the FNCLCC PACS 01 Trial | Q66829419 | ||
| P433 | issue | 9676 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 1662-1663 | |
| P577 | publication date | 2009-05-01 | |
| P1433 | published in | The Lancet | Q939416 |
| P1476 | title | Unravelling the mystery of the TACT trial. | |
| P478 | volume | 373 |
| Q34497992 | Tumors that acquire resistance to low-dose metronomic cyclophosphamide retain sensitivity to maximum tolerated dose cyclophosphamide | cites work | P2860 |
Search more.